Flat quarter, steep decline year-over-year. Biote Corp (NASDAQ: BTMD) reported Q4 fiscal 2025 adjusted EPS of $0.06, matching the prior quarter’s $0.10 but down sharply from $0.37 a year ago, an 83.8% decline. Revenue of $46.4 million came in essentially flat versus the year-ago quarter’s $49.8 million, a 0.6% decline. The medical care facilities provider generated net income of $2.6 million and adjusted EBITDA of $11.7 million on gross profit of $31.5 million. Operating income reached $6.8 million against cost of revenue of $14.9 million. The company’s stock closed at $1.79, unchanged on the day, with trading volume of 277,529 shares.
Profitability collapses from year-ago peak. The earnings trajectory reveals a dramatic deterioration from the Q4 2024 high of $0.37 per share. Sequential quarterly results show EPS of $0.08 in Q1 2025, $0.10 in Q2 2025, $0.22 in Q3 2025, then back to $0.06 in Q4 2025—a volatile pattern with no clear momentum. Revenue has remained range-bound between $48.0 million and $49.8 million across the past five quarters, suggesting the top line has stalled. The company beat estimates in four consecutive quarters through Q3 2025 before this quarter’s inline result, but the year-over-year comparisons paint a troubling picture: profitability has cratered even as revenue held steady. Management issued fiscal 2026 revenue guidance of at least $190 million, implying modest sequential growth from the current run rate of roughly $197 million annualized.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.